Skip to end of metadata
Go to start of metadata

Interactions with the FDA

A priority for the REiNS International Collaboration is to develop and maintain a working relationship with members of the Federal Drug Administration (FDA) as an important stakeholder in neurofibromatosis clinical trial outcomes and study design.  FDA representatives attend our two yearly meetings and present on topics relevant to our work, and REiNS members have presented about our group initiatives at two meetings at the FDA.  These continued interactions are critical to both the REiNS group and the FDA for making progress in the development of clinical trials and approval of new treatments for NF1, NF2, and schwannomatosis.

Specific Topic Meetings

Specific Information from the FDA/EMA

FDA and EMA drug development links

Last updated by Little, Paige (NIH/NCI) [F] on Oct 17, 2022